Loading...
•
Jan 31
Cooper Q1 2025 Earnings Report
CooperCompanies reported revenue growth and improved margins in Q1 2025.
Key Takeaways
CooperCompanies reported Q1 2025 revenue of $964.7 million, a 4% increase year-over-year. The company saw growth across its divisions, with CooperVision revenue up 4% to $646.1 million and CooperSurgical revenue up 3% to $318.6 million. GAAP net income reached $104.3 million, translating to diluted EPS of $0.52, while non-GAAP EPS came in at $0.92. Operating income was $182.0 million, with a 19% operating margin. Free cash flow stood at $101.2 million, driven by strong operational performance.
Total revenue increased 4% year-over-year to $964.7 million.
CooperVision revenue grew 4%, while CooperSurgical revenue rose 3%.
GAAP EPS was $0.52, and non-GAAP EPS increased to $0.92.
Free cash flow reached $101.2 million, reflecting strong cash generation.
Cooper
Cooper
Cooper Revenue by Segment
Cooper Revenue by Geographic Location
Revenue by Segment
Office & Surgical Revenue
CapyFin.comFertility Revenue
CapyFin.comRevenue by Geographic Location
Americas Revenue
CapyFin.comEMEA Revenue
CapyFin.comAsia Pacific Revenue
CapyFin.com Forward Guidance
CooperCompanies expects continued revenue growth in fiscal 2025, with an updated EPS outlook.
Positive Outlook
- Total FY 2025 revenue projected between $4.08B and $4.16B.
- CooperVision revenue expected between $2.73B and $2.79B.
- CooperSurgical revenue forecasted between $1.35B and $1.37B.
- Non-GAAP EPS raised to $3.94 - $4.02 for FY 2025.
- Operational efficiency gains expected to support margin improvements.
Challenges Ahead
- Foreign currency fluctuations may impact revenue growth.
- Macroeconomic uncertainties could affect consumer spending.
- Increased regulatory compliance costs may pressure margins.
- Potential supply chain disruptions could impact inventory levels.
- Interest expense remains a headwind despite a slight decrease.
Revenue & Expenses
Visualization of income flow from segment revenue to net income